DMAC: DiaMedica Therapeutics Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
88 institutions reported holding $87.08M of DiaMedica Therapeutics Inc. on Form 13F (99 the quarter before). 10 opened a new position and 19 sold out. Shares held by institutions: +6%.
| Largest holders | Shares | Value |
|---|---|---|
| COOPERMAN LEON G | 3,450,000 | $24.29M |
| BlackRock, Inc. | 2,252,285 | $15.86M |
| GEODE CAPITAL MANAGEMENT, LLC | 894,115 | $6.30M |
| MILLENNIUM MANAGEMENT LLC | 845,309 | $5.95M |
| STATE STREET CORP | 646,743 | $4.55M |
| Bleichroeder LP | 382,317 | $2.69M |
| VANGUARD CAPITAL MANAGEMENT LLC | 355,523 | $2.50M |
| OSAIC HOLDINGS, INC. | 338,107 | $2.38M |
| NORTHERN TRUST CORP | 327,518 | $2.31M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 251,671 | $1.77M |
Clinical trial readouts
1 Phase 2 or 3 trials by DiaMedica Therapeutics Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-12 (est.) | Recombinant human tissue kallikrein | Acute Stroke | Phase 2/3 | 728 | Recruiting | NCT05065216 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.